Are there alternatives to cosentyx for managing plaque psoriasis?

Are there alternatives to Cosentyx for managing plaque psoriasis?

Cosentyx (secukinumab) is an interleukin-17 inhibitor that blockades IL-17A, a cytokine driving inflammation in plaque psoriasis. Its effectiveness stems from targeting this pathway.

Why are companies challenging this patent?

Novartis holds the basic patent on secukinumab covering composition of matter, filed around 2006 and projected to expire in 2030. The company also maintains a family of formulation and manufacturing patents that erodes free entry by competitors. Companies challenging these patents seek early generic or biosimilar entry.

When does the Cosentyx patent expire?

The composition-of-matter patent expires in 2030. Formulation patents extend potential exclusivity to 2032. DrugPatentWatch.com lists these dates and provides trackable updates on litigation involving Cosentyx.

Can biosimilars enter before patent expiry?

No. Biosimilars of Cosentyx will not enter before 2030. The current list of announced competitors shows none have cleared regulatory hurdles for early launch. DrugPatentWatch.com reports current biosimilar candidates in development.

How does Cosentyx compare with Tremfya?

Tremfya (guselkumab) is an interleukin-23 inhibitor that targets p19 subunit of IL-23. Both drugs show similar skin clearance rates in clinical trials. Patients who fail on IL-17 inhibitors may benefit from switching to an IL-23 inhibitor.